Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic Immunity

被引:31
作者
Barber, Amorette [1 ]
Sentman, Charles L. [1 ]
机构
[1] Dartmouth Med Sch, Dept Microbiol & Immunol, Lebanon, NH 03756 USA
基金
美国国家卫生研究院;
关键词
OVARIAN-CANCER; ADOPTIVE IMMUNOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; INTERFERON-GAMMA; DENDRITIC CELLS; NK CELLS; RECEPTOR; THERAPY; LYMPHODEPLETION;
D O I
10.4049/jimmunol.0900721
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Treatment of mice bearing established ovarian tumors with T cells expressing chimeric NKG2D receptors (chNKG2D) develop protective host immune responses to tumor Ags. In this study, the mechanisms that chNKG2D T cells require to induce host immunity against ovarian tumors and which of the host immune cells are involved in tumor elimination were determined. Treatment with chNKG2D T cells led to a sustained, increased IFN-gamma production by host NK, CD4(+), and CD8(+) T cells in the spleen and at the tumor site and this continued for many weeks after T cell injection. Tumor Ag presentation was enhanced in chNKG2D T cell-treated mice, and there were greater numbers of tumor-specific T cells at the tumor site and in draining lymph nodes after treatment with chNKG2D T cells. The increase in host cell cytokine secretion and Ag presentation was dependent on chNKG2D T cell-derived perforin, IFN-gamma, and GM-CSF. Host immune mechanisms were involved in tumor elimination because inhibition of tumor growth was limited in mice that lacked perforin, IFN-gamma, NK cells, or T and B cells (Rag1(-/-)). There was no role for host-derived GM-CSF or CD1-dependent NKT cells, because mice deficient in these were able to clear tumors as well as treated wild-type B6 mice. In summary, chNKG2D T cells required both cytotoxicity and cytokine secretion as well as the participation of host immune cells for development of a host antitumor immune response and complete efficacy. The Journal of Immunology, 2009, 183: 2365-2372.
引用
收藏
页码:2365 / 2372
页数:8
相关论文
共 30 条
[1]   Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer [J].
Barber, Amorette ;
Zhang, Tong ;
Sentman, Charles L. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (01) :72-78
[2]   Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer [J].
Barber, Arnorette ;
Zhang, Tong ;
DeMars, Leslie R. ;
Conejo-Garcia, Jose ;
Roby, Katherine F. ;
Sentman, Charles L. .
CANCER RESEARCH, 2007, 67 (10) :5003-5008
[3]   NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model [J].
Barber, Melissa A. ;
Zhang, Tong ;
Gagne, Bethany A. ;
Sentman, Charles L. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (10) :6140-6147
[4]   The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis [J].
Blankenstein, T ;
Qin, ZH .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (02) :148-154
[5]   The NKG2D-activating receptor mediates pulmonary clearance of Pseudomonas aeruginosa [J].
Borchers, MT ;
Harris, NL ;
Wesselkamper, SC ;
Zhang, SP ;
Chen, Y ;
Young, L ;
Lau, GW .
INFECTION AND IMMUNITY, 2006, 74 (05) :2578-2586
[6]   Tumor cell recognition by the NK cell activating receptor NKG2D [J].
Bryceson, Yenan T. ;
Ljunggren, Hans-Gustaf .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (11) :2957-2961
[7]   Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens [J].
Dudley, Mark E. ;
Yang, James C. ;
Sherry, Richard ;
Hughes, Marybeth S. ;
Royal, Richard ;
Kammula, Udai ;
Robbins, Paul F. ;
Huang, JianPing ;
Citrin, Deborah E. ;
Leitman, Susan F. ;
Wunderlich, John ;
Restifo, Nicholas P. ;
Thomasian, Armen ;
Downey, Stephanie G. ;
Smith, Franz O. ;
Klapper, Jacob ;
Morton, Kathleen ;
Laurencot, Carolyn ;
White, Donald E. ;
Rosenberg, Steven A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5233-5239
[8]   Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].
Dudley, ME ;
Wunderlich, JR ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Restifo, NP ;
Royal, RE ;
Kammula, U ;
White, DE ;
Mavroukakis, SA ;
Rogers, LJ ;
Gracia, GJ ;
Jones, SA ;
Mangiameli, DP ;
Pelletier, MM ;
Gea-Banacloche, J ;
Robinson, MR ;
Berman, DM ;
Filie, AC ;
Abati, A ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357
[9]   Dendritic cells and cytokines in immune rejection of cancer [J].
Ferrantini, Maria ;
Capone, Imerio ;
Belardelli, Filippo .
CYTOKINE & GROWTH FACTOR REVIEWS, 2008, 19 (01) :93-107
[10]   Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells [J].
Gattinoni, L ;
Finkelstein, SE ;
Klebanoff, CA ;
Antony, PA ;
Palmer, DC ;
Spiess, PJ ;
Hwang, LN ;
Yu, ZY ;
Wrzesinski, C ;
Heimann, DM ;
Surh, CD ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :907-912